Canada markets closed

ARCA biopharma, Inc. (ABIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.5000+0.2400 (+7.36%)
At close: 04:00PM EDT
3.4500 -0.05 (-1.43%)
After hours: 04:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close3.2600
Open3.2900
Bid2.5200 x 200
Ask4.1600 x 200
Day's Range3.1401 - 3.5500
52 Week Range1.5600 - 4.4900
Volume127,796
Avg. Volume1,485,711
Market Cap50.775M
Beta (5Y Monthly)0.96
PE Ratio (TTM)N/A
EPS (TTM)-0.4200
Earnings DateJul 19, 2024 - Jul 23, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

    ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee o

  • GlobeNewswire

    ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

    Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and ORKA-002, potentially best-in-class antibodies targeting IL-23p19 and IL-17A/F, respectively, into clinical trials in 2025 Pre-closing private financing of approximately $275 million anticipated to fund operations thr

  • GlobeNewswire

    ARCA biopharma Announces 2023 Financial Results

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Feb. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2023 financial results and provided a corporate update. In April 2022, the Board of Directors establi